Drug Development

Digital therapeutics 1.0 crashed and burned. By fusing software directly with standard prescriptions, a new hybrid model is rewriting the pharma playbook.

After decades of setbacks, a new drug from Skyhawk Therapeutics shows patients not just slowing decline, but improving. Is this the breakthrough a desperate community has been waiting for?

GT Biopharma secures FDA clearance for a Phase 1 trial of GTB-5550 in multiple myeloma, a strategic pivot for its TriKE® platform, but the trial's start hinges on securing grant funding.

In the race for a 'longevity protein' therapy, a key safety milestone is met. This de-risks the path to the clinic, but what does it mean for the future?

FDA Fast Track for Kestrel's KST-6051 signals more than just a new drug; it reveals a new strategy in the war on cancer, backed by Big Pharma's billions.

A late-stage biotech is betting on a novel idea: what if we could repair eye damage at a structural level? Stuart Therapeutics' PolyCol™ platform aims to do just that.

A new platform promises to cut CRO selection from months to days, tackling a critical bottleneck that delays new medicines. Here's the inside story.

Promising trial data for a novel drug targets a stubborn lung cancer mutation, signaling a major strategic advance for BlossomHill Therapeutics and the oncology field.

TOLREMO's successful Phase I trial for TT125-802 validates a novel strategy against NSCLC, offering new hope by targeting cancer's clever escape routes.

Xylo Bio's new drug for depression enters trials, betting it can rewire the brain without the hallucinogenic burden. Is this the future of mental healthcare?

A small biotech assembles top experts to guide a promising, Sanofi-licensed drug through trials, betting it can solve a stubborn cardiovascular challenge.

With impressive Phase 2 data, Revelyx Bio's ready-to-use recombinant toxin YY003 signals a major technological and practical shift for the aesthetics industry.

As pharma giants dominate the obesity space with GLP-1 drugs, Corbus Pharmaceuticals is betting on a different mechanism. Will its upcoming data rewrite the rules?

Quebec-based Devonian Health Group plans a NYSE American debut, seeking U.S. capital to advance its promising pipeline of autoimmune disease treatments.

A Michigan biotech just patented a way to turn yeast into tiny drug factories inside you. It’s a blueprint for a future without injections or cold chains.

Glucotrack secures $11.5M to fund a breakthrough diabetes monitor, but a look beneath the surface reveals a high-stakes gamble on AI and shareholder value.

A new study reveals an mRNA flu vaccine sustains immune responses for months, a breakthrough that could lead to multi-season protection and end the annual flu shot.

XORTX starts manufacturing its gout drug XORLO™, a pivotal move toward FDA approval. But can it navigate a competitive market and its own financial hurdles?

CSL Seqirus's new flu shot combines three proven technologies. A landmark Lancet study validates its strategic R&D investment in the senior healthcare market.

A French biotech takes a critical step to industrialize a promising therapy for LCAT deficiency, navigating the high-stakes regulatory world of biologics.